Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus

Simple item page
dc.contributor.advisorDinçer, Ayşe Bahar Keleşoğlu
dc.contributor.authorKınıklı, Gülay
dc.contributor.departmentTıp Fakültesitr_TR
dc.contributor.otherİlgen, Ufuk
dc.contributor.otherYayla, Müçteba Enes
dc.contributor.otherAteş, Aşkın
dc.contributor.otherOkatan, İ. E.
dc.contributor.otherYurteri, Emine uslu
dc.contributor.otherTorğutalp, Murat
dc.contributor.otherTurgay, Tahsin Murat
dc.date.accessioned2020-03-13T12:45:11Z
dc.date.available2020-03-13T12:45:11Z
dc.date.issued2018
dc.description.abstractObjectives: The aim of this study was to investigate the association between antiphospholipid antibodies and non-thrombotic and non-gestational manifestations of systemic lupus erythematosus. Methods: Systemic lupus erythematosus patients with persistently positive antiphospholipid antibodies or lupus anticoagulant were identified and grouped as systemic lupus erythematosus with antiphospholipid syndrome (SLE-APS), systemic lupus erythematosus with positive antiphospholipid antibodies/lupus anticoagulant without antiphospholipid syndrome (SLE-aPL), and systemic lupus erythematosus with negative aPLs (SLE-No aPL). Groups were compared in terms of non-thrombotic systemic lupus erythematosus manifestations and laboratory features retrospectively. Results: A total of 150 systemic lupus erythematosus patients, 26 with SLE-APS, 25 with SLE-aPL, and 99 with SLE-No aPL, were identified. Livedo reticularis, neurologic involvement, and thrombocytopenia were more common in antiphospholipid antibody positive systemic lupus erythematosus cases. Malar rash, arthritis, and pleuritis were more common in the SLE-No aPL, SLEAPS, and SLE-aPL groups, respectively. Positivity rates and titers of specific antiphospholipid antibodies did not differ between the SLE-APS and SLE-aPL groups. Conclusions: Presence of antiphospholipid syndrome or persistent antiphospholipid antibodies may be related to non-thrombotic and non-gestational systemic lupus erythematosus manifestations. Patients with systemic lupus erythematosus plus antiphospholipid syndrome and persistent antiphospholipid antibodies without antiphospholipid syndrome also differ in terms of systemic lupus erythematosus manifestations.tr_TR
dc.description.indexScopus
dc.description.indexPubmed
dc.identifier.endpage669tr_TR
dc.identifier.issn/e-issn0961-2033
dc.identifier.issn/e-issn1477-0962
dc.identifier.startpage665tr_TR
dc.identifier.urihttps://doi.org/10.1177/0961203317734924tr_TR
dc.identifier.urihttp://hdl.handle.net/20.500.12575/70427
dc.identifier.volume27tr_TR
dc.language.isoentr_TR
dc.publisherSAGE Publications Ltdtr_TR
dc.relation.isversionof10.1177/0961203317734924tr_TR
dc.relation.journalLupustr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıtr_TR
dc.subjectAntiphospholipid antibodytr_TR
dc.subjectantiphospholipid syndrometr_TR
dc.subjectlupus anticoagulanttr_TR
dc.subjectSystemic lupus erythematosustr_TR
dc.titleAntiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosustr_TR
dc.typeArticletr_TR

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
0961203317734924.pdf
Size:
83.23 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.62 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Makale
PubMed İndeksli Yayınlar
Scopus İndeksli Yayınlar